DPA (ácido docosapentaenoico)

Docosapentaenoic Acid (DPA, 22:5n-3): A Comprehensive Reference

1. Identity: Chemical Name, Structure, and Isomers

Docosapentaenoic acid (DPA) is the common name for any straight, open-chain polyunsaturated fatty acid (PUFA) containing 22 carbon atoms and five double bonds. DPA designates two primary isomers: all-cis-4,7,10,13,16-docosapentaenoic acid (the omega-6 form, or n-6 DPA) and all-cis-7,10,13,16,19-docosapentaenoic acid (the omega-3 form, or n-3 DPA); the n-3 and n-6 designations describe the position of the first double bond relative to the methyl end of the molecule, distinguishing two separate PUFA classes — the omega-6 and omega-3 fatty acids, respectively.

Unless otherwise specified, "DPA" in nutritional and clinical literature almost universally refers to the omega-3 isomer, n-3 DPA (22:5n-3). This compound carries the trivial name clupanodonic acid and is an intermediary between eicosapentaenoic acid (EPA, 20:5 ω-3) and docosahexaenoic acid (DHA, 22:6 ω-3). Its full IUPAC chemical name is (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoic acid, with molecular formula C₂₂H₃₄O₂ and featuring 22 carbon atoms with five cis double bonds.

The omega-6 isomer, all-cis-4,7,10,13,16-docosapentaenoic acid, is known as Osbond acid. It is an omega-6 fatty acid formed by an elongation and desaturation of arachidonic acid (20:4 ω-6). In mammals, clupanodonic acid (n-3 DPA) deficiency is accompanied by an increase of the Osbond acid isomer; the Osbond acid/DHA ratio is thus used as a marker of dietary DHA sufficiency. Mammals, including humans, cannot interconvert the n-3 and n-6 PUFA classes and therefore must obtain essential PUFA from both classes to maintain normal health.

Structurally, the n-3 DPA molecule is characterised by a chain of 22 carbon atoms and five double bonds (chemical notation 22:5n-3), a structure that resembles EPA (20 carbons, 5 double bonds) and DHA (22 carbons, 6 double bonds). DPA therefore shares the same number of carbons as DHA and the same number of double bonds as EPA.

2. Natural Sources and Dietary Occurrence

Fish oils and long-chain omega-3 fatty acids are well recognised for their critical role in human diets. DPA has always been a part of healthy nutrition, since infants obtain almost as much DPA as DHA from human milk. Fish oil supplements and ingredients, oily fish, and grass-fed beef can serve as the primary DPA sources for the general population.

Naturally occurring DPA is present in various seafood sources, including fatty fish such as salmon (approximately 393 mg per 100 g) and mackerel (over 200 mg per 100 g), as well as fish oil supplements like menhaden oil (about 4.9% DPA content). DPA has drawn the attention of scientists because it is present in relatively high levels in the diet of Greenland Inuits, a population with exceptionally low incidence of cardiovascular disease. The USDA National Nutrient Database indicates DPA is present in marine oils, with menhaden oil documented as the richest fish oil source of the compound.

Seal and whale oil, while less common in Western diets, are some of the richest natural sources of DPA. Fatty fish including salmon, mackerel, herring, and sardines are natural sources, as is grass-fed lamb and related ruminant meats, which contain trace amounts of DPA.

Although DPA levels in fish oils are substantially lower than those of EPA and DHA, concentrated DPA products are now becoming commercially available, and DPA-based drugs are under development. Algae-based supplements also represent a plant-derived alternative source of DPA.

3. Metabolic Position and Biosynthesis

DPA serves as a key intermediate in the metabolic pathway converting eicosapentaenoic acid (EPA, 20:5n-3) to docosahexaenoic acid (DHA, 22:6n-3) through elongation and desaturation processes in mammalian tissues. In the body's metabolism, DPA occupies an intermediate position in the conversion pathway of omega-3s. It is formed when EPA is elongated by two carbon units, which positions DPA as a precursor that is then further modified to create DHA through a final desaturation step.

DPA is biosynthesised from alpha-linolenic acid (ALA, 18:3n-3) via enzymatic steps involving delta-5 and delta-6 desaturases and elongases, though its endogenous production is limited, making dietary intake important. The process begins with the elongation of EPA by elongase ELOVL5 to form 22:5n-3. Key enzymes in these pathways include delta-5 and delta-6 desaturases (encoded by FADS1 and FADS2 genes, respectively) for introducing double bonds, as well as elongases ELOVL2 and ELOVL5 for chain lengthening from shorter precursors like alpha-linolenic acid.

A distinctive feature of DPA is its bidirectional metabolic flexibility. Enzymes can elongate and desaturate EPA to DPA, and the body can also retroconvert DPA back to EPA when needed. This bidirectional flow makes DPA a flexible reservoir that may help maintain EPA availability in tissues while also taking part in its own set of actions. In vitro, n-3 DPA is retroconverted back to EPA, though it does not appear to be readily metabolised to DHA. In vivo studies have shown limited conversion of n-3 DPA to DHA, mainly in the liver, but retroconversion to EPA is evident in a number of tissues.

4. Traditional and Historical Use

DPA, as an isolated dietary supplement, is a modern discovery with no distinct traditional or folk medicine history as a named, intentionally used substance. However, the foods that constitute its primary source — marine animals, fatty fish, and sea mammals — have deep roots in the diets and health traditions of circumpolar peoples.

As a result of anecdotal reports of their low incidence of coronary heart disease, Bang and Dyerberg began to study the Greenland Inuit (Eskimo) population in the late 1960s. Their pioneering findings confirmed the anecdotal evidence: Inuits had lower incidences of myocardial infarction, better lipid profiles, reduced platelet activity, and lower incidence of immune and inflammatory diseases compared with western controls. These findings were attributed to the Inuit diet, and specifically to the large quantities of seal and whale meat consumed. Eventually it was deduced that marine n-3 fatty acids found in the seal and whale meat were the main protective agents against cardiovascular heart disease.

What had been forgotten in the ensuing years of omega-3 research was that Inuit seal meat also contained high concentrations of DPA in addition to the more familiar EPA and DHA. DPA was not recognised as a discrete, biologically significant compound separate from EPA and DHA until relatively recently. In the last three decades, scientific studies focused on oils that contained mixtures of fatty acids, or on purified EPA and DHA, while the amount of research focused on DPA was limited. This means that whatever protective benefits were attributed to traditional marine-heavy diets were likely the product of combined EPA, DHA, and DPA intake, without DPA being identified as a discrete contributor until modern analytical chemistry made such distinctions possible.

DPA has always been a part of healthy nutrition, given that infants obtain almost as much DPA as DHA from human milk — a fact that underscores its longstanding presence in human dietary physiology across all populations and time periods, even if its separate identity went unrecognised.

5. Key Constituents, Active Compounds, and Mechanisms of Action

DPA (22:5n-3) is itself the primary active compound under study; it is not a botanical extract with multiple secondary metabolites, but rather a single polyunsaturated fatty acid whose mechanisms arise from its structural properties, metabolic conversions, and oxygenated derivatives.

5.1 Cell Membrane Incorporation and Structural Effects

As a "long-chain" molecule with 20 or more carbons, DPA has the ability to embed in cell membranes and influence fluidity, receptor function, and signalling. These fatty acids participate in diverse processes including cell membrane structure, eicosanoid metabolism, gene transcription, and resolution of inflammation.

5.2 Specialised Pro-Resolving Mediators (SPMs)

One of the most scientifically significant aspects of DPA's mechanism involves its role as a precursor for specialised pro-resolving mediators (SPMs). EPA, DPA, and DHA are precursors of specialised pro-resolving mediators (SPMs), including resolvins, protectins, and maresins of different kinds, which do not merely suppress inflammation but actively initiate resolution of inflammation and tissue repair.

DPA (22:5n-3) can be converted to resolvins, first by 17-lipoxygenation to 17-hydroperoxy-8Z,10Z,13Z,15E,19Z-docosapentaenoic acid followed by a 5-lipoxygenase-like reaction to yield three metabolites, of which the most abundant is designated RvD1n-3 DPA. Oxygenated metabolites derived from EPA, DPA, and DHA — termed neuroprotectins, resolvins, and maresins — are reported to have potent anti-inflammatory and immunoregulatory actions at concentrations in the nanomolar to picomolar range.

The active process of resolution of inflammation by SPMs biosynthesised from the ω-3 PUFAs EPA, DHA, and n-3 DPA is a dynamic and programmed response, not merely passive dilution of chemoattractants — a paradigm shift in biomedical thinking. Resolving inflammatory exudates convert these ω-3 PUFAs to families of structurally distinct signalling molecules: resolvins, protectins, and maresins. SPMs are agonists in the resolution phase of inflammation and exert their bioactions by stereoselective interaction with G-protein-coupled receptors (GPCRs), limiting the infiltration of polymorphonuclear neutrophils and enhancing the clearance of apoptotic cells by phagocytosis.

N-3 docosapentaenoic acid has been found to be a substrate for the biosynthesis of several novel families of specialised pro-resolving mediators, one example being PD1n-3 DPA (a protectin). These lipid mediators govern the resolution of inflammation as potent and stereoselective agonists toward individual G-protein-coupled receptors, resulting in potent anti-inflammatory activities demonstrated in many human disease models. Specialised pro-resolving mediators are oxygenated polyunsaturated products formed in stereoselective and distinct biosynthetic pathways initiated by various lipoxygenase and cyclooxygenase enzymes.

5.3 Platelet Aggregation Inhibition

Platelet aggregation is an early event in the development of thrombosis and is initiated by thromboxane A2. An in vitro study conducted in rabbit platelets showed that EPA, DPA, and DHA inhibited collagen- or arachidonic acid-stimulated platelet aggregation in a dose-dependent manner, with DPA being the most potent inhibitor and possibly ten times more powerful than EPA in inhibiting platelet aggregation. A further study conducted on human whole blood corroborated these earlier findings.

N-3 DPA can be metabolised by lipoxygenase in platelets to form 11-hydroxy and 14-hydroxy-DPA metabolites. It has also been reported that n-3 DPA is effective — more so than EPA and DHA — in inhibiting platelet aggregation. N-3 DPA also increased the LOX pathway and may act as a strong inhibitor of COX-1 and COX-2 activities, leading to decreased platelet aggregation and active aortic tension.

5.4 Endothelial Cell Migration and Vascular Biology

Endothelial cell (EC) migration and proliferation are important processes in the control of the wound-healing response of blood vessels. DPA has been shown to be a potent stimulator of EC migration. Direct pretreatment of endothelial cells with DPA (0.01–1.0 μg/ml) resulted in a dose-dependent increase in migration in response to fetal bovine serum. N-3 DPA stimulated the migration of endothelial cells, whose migration and proliferation are involved in the healing response of blood vessels. The treatment of aortic endothelial cells with n-3 DPA also appeared to modulate vascular endothelial growth factor (VEGF) activity.

5.5 Lipid Metabolism and Triglyceride Lowering

DPA, particularly the n-3 isomer, has demonstrated potential in improving lipid profiles by lowering triglycerides and non-HDL cholesterol levels. In supplementation studies involving omega-3 fatty acids enriched with DPA, triglyceride reductions of 10–20% have been observed, alongside modest increases in HDL cholesterol. Pre-clinical evidence suggests that DPA supplementation may have beneficial effects on triglycerides similar to those of EPA and DHA. An inverse association between red blood cell (RBC) DPA concentration and blood triglycerides has also been documented.

5.6 Neuroinflammation: Microglia Modulation and BDNF Pathways

N-3 DPA may protect neurons from neuroinflammation-induced damage by balancing microglia M1 and M2 polarisations, inhibiting microglia-NF-κB and MAPK p38 while activating neuron-BDNF/TrkB-PI3K/AKT pathways. DPA significantly downregulated the mRNA expression of pro-inflammatory factors including interleukin (IL)-6, IL-1β, tumour necrosis factor (TNF)-α, inducible nitric oxide synthase (iNOS), and cyclooxygenase 2 (COX-2) in cells stimulated by lipopolysaccharide. DPA also increased the expression of anti-inflammatory cytokine IL-10 in a dextran sulphate sodium-induced colitis model.

5.7 Gene Expression Modulation

Docosapentaenoic acid is also involved in altering gene expression — especially genes that reduce the synthesis of fat in the body — and plays a part in reducing the expression of inflammatory genes.

5.8 DPA as a Metabolic Reservoir for EPA and DHA

The first-ever human supplementation trial with 99.8% pure DPA showed that its consumption significantly increased the levels of EPA, DPA, and DHA in blood plasma of the participants. DPA was both retroconverted to EPA and further elongated to DHA, leading the authors to suggest that DPA may serve as a reservoir or pool for EPA and DHA, which can be used by the body as needed.

6. Scientific Evidence by Area of Use

6.1 Cardiovascular Health

Epidemiological Evidence

Studies of plasma and serum n-3 DPA concentrations indicate that n-3 DPA likely plays a role in influencing health outcomes that are responsive to EPA and DHA. Lower serum concentrations of DHA + n-3 DPA and n-3 DPA alone have been associated with greater risk of acute coronary events and myocardial infarction, respectively. Emerging evidence suggests that DPA, the intermediate fatty acid species between EPA and DHA, may also play a role in imparting the health benefits previously attributed solely to EPA and DHA. Although evidence remains limited, a lower serum concentration of n-3 DPA has been associated with greater risk of myocardial infarction (Oda et al., 2005).

Inverse associations have also been found between DPA and intermediate cardiovascular disease risk factors, such as the inflammatory marker C-reactive protein. Clinical studies reported that DPA concentration in red blood cells was inversely associated with high-sensitivity C-reactive protein and TNF-α, which positively correlated with a lower risk of systemic inflammation in the James Bay Cree population.

Atrial Fibrillation

A consortium study examining the prospective associations of blood or adipose tissue levels of EPA, DPA, and DHA with incident atrial fibrillation (AF) used participant-level data from a global consortium of 17 prospective cohort studies, each with baseline data on blood or adipose tissue omega-3 fatty acid levels and AF outcomes. Among 54,799 participants from 17 cohorts, 7,720 incident cases of AF were ascertained after a median 13.3 years of follow-up.

Higher dietary intake of combined EPA + DHA + DPA was associated with a lower risk of developing AF: the median intake was 219 mg/d, and the protective effect was most notable up to an intake of approximately 750 mg/day (11% reduction in AF risk at this intake), indicating a possible threshold effect.

In contrast, one earlier prospective study involving plasma phospholipid measurement found that in multivariable Cox models, the relative risk in the top versus lowest quartile of total n-3 PUFAs (EPA + DPA + DHA) was 0.71 (95% CI: 0.57–0.89; P for trend=0.004), and of DHA levels was 0.77 (95% CI: 0.62–0.96; P for trend=0.01). Eicosapentaenoic acid and docosapentaenoic acid levels alone were not significantly associated with incident AF; it was total n-3 PUFAs and DHA that showed graded and linear inverse associations. This finding illustrates that DPA's role in AF prevention has not been independently established, and its contribution may be exerted principally as part of the total n-3 PUFA pool.

Lipid Profiles: Human Evidence

Results from recent studies have revealed that n-3 DPA also has favourable effects on cardiometabolic health, and a search of PubMed, Embase, and the Cochrane Library suggests DPA has a favourable effect on cardiometabolic health in a different way to other long-chain n-3 PUFAs such as EPA and DHA.

A published study examined RBC DPA in healthy adults and found an inverse association between RBC DPA content and both triglycerides and C-reactive protein. In this work, supplement groups were defined by daily dose of EPA + DHA provided by one-gram oil capsules, with participants in one arm consuming six capsules daily for five months, and in another consuming four capsules daily for eight weeks. The study demonstrated that n-3 fatty acid supplementation dose-dependently increased RBC DPA content.

Thrombosis and Antithrombotic Effects

N-3 PUFAs may contribute to atherosclerotic cardiovascular disease prevention through multiple mechanisms, including lowering plasma triglyceride levels, anti-inflammatory effects, antithrombotic effects, and effects on endothelial function. DPA specifically has demonstrated platelet-inhibitory effects in vitro that equal or exceed those of EPA and DHA, as described in section 5.3. However, dedicated human trials specifically isolating DPA's antithrombotic effects remain absent as of the available literature.

Evidence strength summary for cardiovascular health: Epidemiological associations are supported by multiple cohort studies and meta-analyses at the level of total n-3 PUFAs; DPA's independent contribution to cardiovascular risk reduction is suggested by epidemiology and mechanistic studies but has not yet been confirmed in dedicated randomised controlled trials using purified DPA.

6.2 Inflammation and Immune Function

Once lipoxins are produced, the resolution phase of inflammation continues with the synthesis of other pro-resolving mediators derived from DHA, DPA, and EPA: resolvins, protectins, and maresins. During acute inflammation, neutrophils and monocytes/macrophages produce a distinct class of pro-resolving mediators derived from DHA, EPA, and n-3 DPA, orchestrating the immunological events underlying the shutdown of the inflammatory response.

Causational in vitro studies showed that purified DPA, when applied to platelets or cell lines, reduced platelet aggregation, stimulated endothelial cell migration, and reduced inflammation. It was reported that DPA treatment inhibited platelet aggregation more efficiently than EPA or DHA.

The limited studies point toward a positive role that DPA supplementation can play in these processes and that is separate and distinct from traditional supplementation with DHA and EPA.

Evidence strength: Mechanisms involving DPA-derived SPMs (resolvins of the D-series, protectin PD1n-3 DPA) are well-characterised in vitro and in animal models at the biochemical level. Direct human clinical trial evidence for DPA-mediated immune modulation is lacking. Most available data are pre-clinical or derive from studies using mixed omega-3 preparations.

6.3 Neurological and Cognitive Health

As major components of neuronal membranes and key modulators of neuroinflammation, oxidative stress, and neurogenesis, omega-3 PUFAs, particularly DHA, EPA, and DPA, may exert beneficial and neuroprotective effects on the aging brain. Rodent studies have shown that n-3 PUFA supplementation improves neurogenesis and synaptogenesis, executive functions, and learning abilities, while n-3 PUFA deficiency is associated with memory deficits and impaired hippocampal plasticity.

Studies in mammals, platelets, and cell cultures have demonstrated that DPA reduces platelet aggregation, improves lipid metabolism, endothelial cell migration, and resolution of chronic inflammation. Other in vivo and in vitro studies have shown that DPA can improve neural health.

The growth and development of the central nervous system is particularly dependent upon the presence of adequate amounts of the very long-chain, highly unsaturated fatty acids DPA and DHA. Attention deficit hyperactivity disorder and failures in the development of the visual system are cited as examples of this dependency in essential fatty acid deficiencies.

Findings have suggested that the antidepressant or neuroprotective effects of EPA were not mediated solely by DHA production, but rather by EPA and/or DPA.

Evidence strength: DPA's neural health role is currently supported primarily by animal models (rodent studies), in vitro mechanistic work, and inference from human studies of mixed omega-3 preparations. There are no dedicated clinical trials in human subjects examining DPA alone for cognitive function or neurological endpoints. Evidence is preliminary.

6.4 Systemic Inflammation Markers

In cell-based research, DPA significantly downregulated the mRNA expression of pro-inflammatory factors (IL-6, IL-1β, TNF-α, iNOS, and COX-2) in RAW264.7 cells stimulated by lipopolysaccharide, and increased the expression of anti-inflammatory cytokine IL-10 in a dextran sulphate sodium-induced colitis model. Inverse associations have been found between circulating DPA levels and C-reactive protein, an intermediate CVD risk marker.

6.5 Role in Liver and Lipid Gene Expression

DPA is the third most prevalent species of polyunsaturated fatty acid in certain pharmaceutical omega-3 compositions. Although DPA is an intermediate in the biosynthetic pathway from EPA to DHA, surprisingly little is known about DPA's specific biological effects. Gene expression profiling experiments in hepatocarcinoma cells have been used to examine DPA's effects on hepatic gene expression related to lipid metabolism, with the aim of clarifying its potential clinical contribution.

Preclinical data suggest that intake of omega-3 PUFAs including EPA, DPA, and DHA could prevent hepatocarcinogenesis by inhibiting the pro-inflammatory cyclooxygenase (COX)-2 enzyme, which in turn inhibits endogenous biosynthesis of prostaglandins and β-catenin signalling pathways, while simultaneously stimulating the endogenous biosynthesis of pro-resolution lipid mediators. This is an area of early, largely pre-clinical inquiry.

7. Body Systems Associated with DPA

Omega-3 long-chain PUFAs — including EPA, DHA, and DPA — play an important role in the growth and development of the brain, the regulation of blood pressure, renal function, blood clotting, and inflammatory and immunological reactions. Based on the available scientific literature, DPA has been associated with the following body systems:

• Cardiovascular system: Platelet function, triglyceride metabolism, endothelial cell biology, blood pressure regulation, and atherosclerotic risk.
• Immune and inflammatory systems: Production of specialised pro-resolving mediators (resolvins, protectins, maresins); modulation of macrophage polarisation (M1/M2 balance); suppression of pro-inflammatory cytokines.
• Nervous system: Neuronal membrane composition, neuroinflammation modulation, synaptic maintenance, and the BDNF/TrkB-PI3K/AKT signalling pathway.
• Hepatic system: Lipid gene expression, triglyceride biosynthesis, and potentially hepatocarcinogenesis pathways.
• Haematological system: Platelet aggregation inhibition, antithrombotic effects.
• Renal system: Referenced in EFSA's overview of n-3 LCPUFA functions.

8. Dosage Forms and Doses Reported in Studies

DPA is not currently the subject of wide standardised supplementation guidelines, and government authorities have not established recommended daily intakes specific to DPA alone. While many government agencies worldwide offer guidelines for DHA and EPA intake, few currently recommend the intake of DPA. Only Australia and New Zealand offer specific guidelines for DPA intake along with EPA and DHA.

DPA is consumed primarily as a minor component of fish oil, marine oil, and omega-3 supplements, rather than as a standalone supplement. Although DPA levels in fish oils are substantially lower than those of EPA and DHA, concentrated DPA products are now becoming commercially available, and DPA-based drugs are under development.

In human research to date:

• The first-ever human supplementation trial utilised 99.8% pure DPA and demonstrated that its consumption significantly increased the levels of EPA, DPA, and DHA in blood plasma. The specific dose administered in that trial is not specified in the available published summaries.
• In studies examining RBC DPA responses to omega-3 supplementation, one arm used six one-gram oil capsules daily (providing EPA + DHA) for five months, and another used four one-gram oil capsules daily for eight weeks. These studies measured DPA as an outcome rather than providing DPA as the primary intervention.
• In the OMEMI trial, elderly patients with recent acute myocardial infarction were randomised to 1.8 g/day of EPA/DHA or control (corn oil) for 2 years — a study in which DPA appeared as a co-measured fatty acid rather than the primary supplement.
• In the EVOLVE trial, a 12-week, double-blind, olive oil-controlled study of patients with severe hypertriglyceridaemia (triglyceride levels in the range 500–2,000 mg/dL), a DPA-enriched omega-3 pharmaceutical composition was used, with percent change in plasma triglyceride levels as the primary endpoint.
• The pharmaceutical omega-3 composition Epanova® used in clinical bioavailability studies contained DPA as a component; the batch used in the ECLIPSE crossover trial comprised 57.3% (a/a) EPA, 19.6% (a/a) DHA, and 6.2% (a/a) DPA in free acid form, administered as a 4 g dose.

Research indicates that death rate is reduced in patients who were receiving EPA and DHA with doses ranging from 500 mg to 1.8 g per day for a duration of 1–5 years. However, this finding pertains to EPA and DHA supplementation broadly; DPA-specific dose-response data from human trials remain extremely limited.

9. Safety Considerations and Interactions

9.1 Regulatory Safety Assessment (EFSA)

Following a request from the European Commission, EFSA's Panel on Dietetic Products, Nutrition and Allergies was asked to deliver a scientific opinion on the Tolerable Upper Intake Level (UL) of the n-3 LCPUFAs eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid. Available data were found to be insufficient to establish a UL for n-3 LCPUFA (individually or combined) for any population group. At observed intake levels, consumption of n-3 LCPUFA has not been associated with adverse effects in healthy children or adults.

The EFSA Panel noted that at intake levels obtained from foods, n-3 LCPUFA has not been associated with adverse effects in healthy adults and children. It concluded that supplemental intakes of EPA and DHA combined at doses up to 5 g a day do not raise safety concerns for adults. DPA was formally included in the scope of this opinion (EPA + DHA + DPA), but DPA-specific safety limits were not separately established due to insufficient data.

The panel stated that available data are insufficient to establish a UL for the omega-3 long-chain polyunsaturated fatty acids individually or combined for any population group. It specified that there was no significant risk with long-term supplemental intakes of EPA and DHA combined up to about 5 g/day, supplemental intakes of EPA alone up to 1.8 g/day, and DHA alone up to about 1 g/day do not raise safety concerns.

9.2 US FDA Guidance

The US FDA recommends that consumers stay under 3 g/day of total EPA and DHA consumption. DPA is not separately addressed in US FDA guidance; it is implicitly captured within total marine omega-3 recommendations.

9.3 Bleeding and Anticoagulation

Because DPA is among the most potent inhibitors of platelet aggregation identified among the omega-3 fatty acids in vitro (more potent than EPA or DHA in some in vitro models), it is expected to carry comparable or potentially heightened bleeding-related cautions as other long-chain omega-3s. Long-term supplemental intakes of EPA and DHA combined up to about 5 g/day do not appear to increase the risk of spontaneous bleeding episodes or bleeding complications according to EFSA's assessment of available data. However, this does not apply to DPA specifically as a highly concentrated supplement, as such preparations have not been the subject of large human safety trials. Interactions between high-dose omega-3 supplementation (including DPA-enriched formulas) and anticoagulant or antiplatelet medications (e.g., warfarin, aspirin, clopidogrel) are theoretically plausible given the demonstrated inhibition of platelet aggregation, though the existing evidence base does not allow quantification of clinical bleeding risk from DPA alone.

9.4 Atrial Fibrillation Risk at High Doses

While updated cohort data and recent meta-analyses consistently link higher intake or circulating levels of EPA and DHA to reduced risk of cardiovascular events, evidence from RCTs indicates that high-dose supplementation may be associated with an increase in atrial fibrillation (AF) risk. Whether DPA as a component of high-dose formulations contributes to this AF signal has not been independently assessed.

9.5 Lipid Oxidation

The findings from animal studies imply that optimal neuroprotection may be achieved at moderate omega-3 levels, potentially reducing risks of bleeding and lipid peroxidation associated with high-dose supplementation. As a highly unsaturated fatty acid, DPA is susceptible to lipid oxidation, a quality and stability consideration relevant to manufacturing and storage of DPA-enriched preparations.

9.6 DPA and Existing Omega-3 Interactions

An enhancement in circulating levels of n-3 DPA is followed by a simultaneous decrease in the level of DHA due to single nucleotide polymorphisms observed in the gene encoding for the fatty acid elongase 2 (ELOVL2) enzyme. This suggests that the balance between DPA and DHA at the tissue level can be influenced by genetic variation and may affect the practical outcomes of supplementation. Individuals with FADS or ELOVL gene variants may differ in their conversion efficiency between DPA, EPA, and DHA.

9.7 Gaps in Independent Safety Data

N-3 DPA has not been extensively studied because of the limited availability of the pure compound. A human supplementation trial with 99.8% pure DPA suggested that it serves as a storage depot for EPA and DHA in the human body. Future randomised controlled human trials with purified DPA will help clarify its effects on human health. The field therefore lacks the depth of independent human safety and pharmacovigilance data available for EPA and DHA individually. Safety inferences for DPA are largely drawn from the broader n-3 LCPUFA literature rather than from DPA-specific clinical trials.

10. Current Research Status and Evidence Limitations

Epidemiological studies show that, similar to EPA and DHA, DPA is linked to various improvements in human health, perhaps owing to its structural similarity to the other two molecules. While the majority of research work focused on EPA and DHA as the active compounds, emerging research has begun to elucidate the specific role that DPA plays in physiological processes and its differences from the other omega-3 fatty acids.

The primary limitations of the DPA evidence base as of the mid-2020s are:

• Scarcity of purified DPA human trials: Most human evidence derives from studies using fish oils or mixed omega-3 preparations in which DPA is a minor component, making it impossible to attribute observed effects specifically to DPA.
• Predominance of pre-clinical data: The most detailed mechanistic insights — including platelet inhibition potency comparisons, SPM biosynthesis, and neuroinflammation modulation — are from in vitro studies or animal models.
• Epidemiological confounding: DPA levels in blood are correlated with EPA and DHA levels, making it difficult to statistically isolate DPA's independent contribution in observational cohorts.
• No established dietary reference intake: Most international regulatory bodies have not set specific intake recommendations for DPA, and the EFSA explicitly noted that available data were insufficient to set a tolerable upper intake level for DPA specifically.

Future randomised controlled human trials with purified DPA will help clarify its effects on human health. They may confirm the available evidence pointing to its nutritional and biological functions, unique or overlapping with those of EPA and DHA.

References

• Kaur G, Cameron-Smith D, Garg M, Sinclair AJ. Dietary sources, current intakes, and nutritional role of omega-3 docosapentaenoic acid. Lipid Technology, 2015. PMC4467567
• Drouin G, Catheline D, Pédrono F, et al. A review of the biologic and pharmacologic role of docosapentaenoic acid n-3. Prostaglandins Leukot Essent Fatty Acids, 2014. PMC4162505
• A review of the biologic and pharmacologic role of docosapentaenoic acid n-3 — PubMed PMID 25232466
• Dietary sources, current intakes, and nutritional role of omega-3 docosapentaenoic acid — PubMed PMID 26097290
• Brenna JT, et al. Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation. PMC4555130
• n-3 docosapentaenoic acid (DPA) intake and relationship to plasma long-chain n-3 fatty acid concentrations in the United States: NHANES 2003–2014. PMC6681819
• Biology and Total Synthesis of n-3 Docosapentaenoic Acid-Derived Specialized Pro-Resolving Mediators. MDPI Molecules 2024. PMC11206527
• Biology and Total Synthesis of n-3 Docosapentaenoic Acid-Derived Specialized Pro-Resolving Mediators. Molecules 2024, 29(12), 2833
• ω-3 DPA Protected Neurons from Neuroinflammation by Balancing Microglia M1/M2 Polarizations through Inhibiting NF-κB/MAPK p38 Signaling and Activating Neuron-BDNF-PI3K/AKT Pathways. PMC8619469
• Uncommon Fatty Acids and Cardiometabolic Health. PMC6213525
• N-3 Fatty Acids (EPA and DHA) and Cardiovascular Health — Updated Review of Mechanisms and Clinical Outcomes. PMC12628397
• Dietary and Pharmacological Fatty Acids and Cardiovascular Health. PubMed PMID 31678992
• Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation. JACC 2023
• Association of Plasma Phospholipid Long-Chain Omega-3 Fatty Acids With Incident Atrial Fibrillation in Older Adults. Circulation (AHA Journals)
• EFSA NDA Panel. Scientific Opinion on the Tolerable Upper Intake Level of EPA, DHA and DPA. EFSA Journal 2012;10(7):2815
• EFSA assesses safety of long-chain omega-3 fatty acids. EFSA Press Release, July 2012
• EFSA NDA Panel. Scientific Opinion on the tolerable upper intake level for supplemental docosahexaenoic acid. EFSA Journal 2026;24(1):e9858
• LIPID MAPS. Protectins, Resolvins and Maresins — Specialized Pro-Resolving Mediators
• Docosapentaenoic Acid — ScienceDirect Topics overview
• Kanayasu-Toyoda T, Morita I, Murota S. Docosapentaenoic acid (22:5, n-3), an elongation metabolite of EPA, is a potent stimulator of endothelial cell migration on pretreatment in vitro. Prostaglandins Leukot Essent Fatty Acids 1996;54(5):319–325
• Docosapentaenoic acid — Wikipedia (chemical identity and isomer detail)
• Docosapentaenoic acid — WikiDoc (chemical nomenclature and sources)
• Effects of Omega-3 Fatty Acid Supplementation on Cognitive Functions and Neural Substrates. Frontiers in Aging Neuroscience 2016
• DPA drawing attention as an omega-3 healthy fat. Natural Products Insider
• Structures of Omega-3 Fatty Acids. DHA/EPA Omega-3 Institute